Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
By Phase
3 drugs in development
By Therapeutic Area
top 3
R&D Momentum
76/100
Pipeline Velocity
50/100
Trial Completion Rate
71/100
Pipeline Concentration
38/100
Pipeline Freshness
64/100
Strategic Signals
Activity
Last 14 days
Water Vapor Thermotherapy vs. Combination Pharmacotherapy for Symptomatic Benign Prostatic Hyperplasia Refractory to Alpha Blocker Monotherapy in Sexually Active Men: A Multicenter Randomized Controlled Trial
Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy
Deep Brain Stimulation (DBS) Retrospective Outcomes Study
SpaceIT Hydrogel System for Perirectal Spacing in Subjects With Low to Intermediate Risk Prostate Cancer Undergoing External Beam Radiotherapy (EBRT)
Patient Retrospective Outcomes (PRO)
Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
A 5-year Superion™ IDS Clinical Outcomes Post-Approval Evaluation (SCOPE)
Stone and Laser Therapies Post-Market Study
IT Matters: The Erectile Restoration Registry
Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss
Prospective, Randomized Clinical Study Evaluating Transoral Outlet Reduction (TORe) and Lifestyle Modification for Patients With Weight Regain Following Roux-en-Y Gastric Bypass
Study to Demonstrate the Value of Paresthesia-Free Fast-Acting Subperception (FAST) and Other SCS Therapies Using WaveWriter™ Spinal Cord Stimulator Systems in the Treatment of Chronic Pain
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Regulatory
Asclera — ASCLERA
Application NDA021201 (NDA)
Asclera — VARITHENA
Application NDA205098 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)